ciprofloxacin + cefepime
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Febrile Neutropenia
Conditions
Febrile Neutropenia
Trial Timeline
Apr 1, 2005 → May 1, 2010
NCT ID
NCT00137787About ciprofloxacin + cefepime
ciprofloxacin + cefepime is a phase 3 stage product being developed by Bayer for Febrile Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00137787. Target conditions include Febrile Neutropenia.
What happened to similar drugs?
4 of 7 similar drugs in Febrile Neutropenia were approved
Approved (4) Terminated (4) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00137787 | Phase 3 | Completed |
Competing Products
8 competing products in Febrile Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 32 |
| Imipenem + Imipenem | Merck | Approved | 43 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 50 |
| Ceftolozane-tazobactam IV | Merck | Approved | 35 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 32 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 35 |
| linezolid + vancomycin | Pfizer | Phase 3 | 40 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 26 |